Carotid artery disease causes up to 30% of all strokes, but severely calcified lesions can make treatment quite complex. The hope is that IVL can be as successful in this area as it has been in the treatment of coronary and peripheral artery disease.
Rakesh Gopinathannair, MD, lead author of a recent American Heart Association scientific statement on cardiac arrhythmias associated with COVID-19, reviewed the latest science associated with this important topic.
Experts hope their findings offer valuable insights that one day lead to improved interventions aimed at preserving brain function in patients with Huntington's.
Rebecca Hahn, MD, discussed key takeaways from the TRISCEND II trial for the Edwards Lifesciences Evoque TTVR valve and shared additional details related to patient selection and implanting the device.
The first patient has been enrolled in a new study of an optimized lead for LBBAP, an area with an explosion of interest in EP as a way to improve patient outcomes.
"This research should be a call to health systems, policymakers and other stakeholders to make it easier for patients—especially the most vulnerable patients—to access PAD-specific care," one cardiologist explained.
Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.
Experts recently uncovered evidence suggesting behaviors such as undereating, binging and purging could be owed to anatomical alterations in parts of the brain.